Hiroaki Kajiyama
Papers
2
Total Citations
320
H-Index
2
About
Hiroaki Kajiyama is a leading figure in the emerging field of plasma oncology, where his work has pioneered the use of cold atmospheric plasma for selective cancer therapy. His research centers on the intersection of biomedical engineering and oncology, specifically investigating how nonequilibrium atmospheric pressure plasma (NEAPP) can induce apoptosis in malignant cells while sparing healthy tissue. His most impactful contribution, a 2012 study garnering over 314 citations, demonstrated that NEAPP treatment could selectively kill ovarian cancer cell lines by triggering programmed cell death, even when applied to a single spot on the culture dish. This breakthrough showed that plasma-generated reactive species could target cancer cells with remarkable specificity, offering a non-invasive alternative to conventional therapies. Kajiyama’s work has profound implications for treating peritoneal dissemination in ovarian cancer, a notoriously difficult condition. By revealing the mechanistic pathways of plasma-induced apoptosis, he has laid the groundwork for clinical applications in minimally invasive oncology. His research continues to inspire a new generation of interdisciplinary scientists exploring the therapeutic potential of physical plasmas.
Research Focus
Key Achievements
Top Papers
- 1
- 2